Experimental rat model representing both acute and chronic heart failure related to autoimmune myocarditis.
The most important clinical manifestation of myocarditis is congestive heart failure. The precise mechanisms of heart failure during myocarditis have not been elucidated because no animal model that would permit in vivo study of hemodynamics in severe active myocarditis has been available. We monitored hemodynamics and left ventricular function in a rat model of experimental autoimmune myocarditis to determine if this model could be useful for the study of in vivo hemodynamics in severe active myocarditis. Lewis rats were immunized with human cardiac myosin suspended in complete Freund's adjuvant. Baseline hemodynamics were measured using an ultraminiature catheter pressure transducer via the right internal carotid artery, 4 weeks after immunization in one group of rats (acute phase) and 3 months after immunization in another group (chronic phase). Untreated rats served as the control group. Hemodynamic measurements were also obtained after infusion of dobutamine in the acute-phase and chronic-phase groups. The heart weight-to-body weight ratios were significantly higher in both the acute-phase group and the chronic-phase group compared with normal control rats. The baseline left ventricular systolic pressure was significantly lower in the chronic phase group than in the control group. Peak dP/dt and peak -dP/dt were significantly lower in both the acute-phase group and the chronic-phase group compared with the control group. Dobutamine significantly increased left ventricular systolic pressure, peak dP/dt, and peak -dP/dt in the chronic-phase group but caused only minor changes in hemodynamic variables in the acute-phase group. In vivo measurements of hemodynamic variables indicated the presence of left ventricular dysfunction in rats with experimental autoimmune myocarditis. This animal model may be useful for the study of both acute heart failure related to acute myocarditis and chronic heart failure due to diffuse myocardial fibrosis.
Koyama
S
S
Division of Cardiology, Tachikawa General Hospital, Nagaoka, Japan.
Kodama
M
M
Izumi
T
T
Shibata
A
A
D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D001327:Autoimmune Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D001794:Blood Pressure / Q000502:physiology; D001835:Body Weight / Q000187:drug effects; D002908:Chronic Disease; D004195:Disease Models, Animal; D004280:Dobutamine / Q000494:pharmacology*; D004562:Electrocardiography / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D009205:Myocarditis / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009218:Myosins; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011917:Rats, Inbred Lew; D013194:Staining and Labeling; D016277:Ventricular Function, Left / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D004280:Dobutamine; D009218:Myosins